AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 Earnings

What happened: A Seeking Alpha analyst reiterated a long-term Buy on AstraZeneca ahead of Q3 earnings, citing product and pipeline strength despite recent setbacks. Key numbers: AZN targets $80bn in revenues by 2030, with 14 current blockbusters and a pipeline that could add 12 more by the decade's end. Why it matters: The analyst says recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US loss of exclusivity, with strong operating margins expected.

A Seeking Alpha analyst reiterated a long-term Buy on AstraZeneca ahead of Q3 earnings, citing product and pipeline strength despite recent setbacks.

The analyst says recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US loss of exclusivity, with strong operating margins expected.